KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) EBITDA (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed EBITDA for 13 consecutive years, with $211.6 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 373.07% to $211.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$27.0 million through Dec 2025, up 88.97% year-over-year, with the annual reading at -$51.7 million for FY2025, 81.48% up from the prior year.
  • EBITDA for Q4 2025 was $211.6 million at Xenon Pharmaceuticals, up from -$90.5 million in the prior quarter.
  • The five-year high for EBITDA was $211.6 million in Q4 2025, with the low at -$90.5 million in Q3 2025.
  • Average EBITDA over 5 years is -$33.6 million, with a median of -$45.7 million recorded in 2022.
  • The sharpest move saw EBITDA crashed 3382.66% in 2021, then soared 373.07% in 2025.
  • Over 5 years, EBITDA stood at -$24.8 million in 2021, then crashed by 74.45% to -$43.3 million in 2022, then fell by 23.92% to -$53.7 million in 2023, then crashed by 44.29% to -$77.5 million in 2024, then skyrocketed by 373.07% to $211.6 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $211.6 million, -$90.5 million, and -$83.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.